-

Agilent BioTek Cytation C10 Confocal Imaging Reader Enhanced with Innovative Water Immersion Technology

Empowering researchers with superior imaging performance for cutting-edge live-cell and three-dimensional applications

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the addition of water immersion and new confocal spinning disk technology to the BioTek Cytation C10 confocal imaging reader. These features improve image quality and results by reducing deleterious effects on live-cell samples and enhancing clarity for thicker samples such as tissues and 3-D spheroids.

In light microscopy, water immersion technology automatically and consistently places a layer of water between the objective lens and the sample. The higher refractive index of water, as compared to air, effectively increases the numerical aperture of the objective lens; this reduces z-axis distortion, resulting in higher image quality and a more true-to-life representation of thick and three-dimensional cell models. Water immersion also benefits researchers who are increasingly turning to physiologically relevant live-cell (as opposed to fixed-cell) applications by reducing exposure times, thus lowering the phototoxic effects traditionally associated with these experiments.

Spinning disk confocal technology improves microscopic images by blocking out-of-focus light from reaching the image sensor. The new deep-sectioning spinning disk (DSD), now available as an option on the Cytation C10, allows researchers to look deeper into thick samples with less out-of-focus blur. The clearer images that result are particularly beneficial in quantitative analysis applications.

“The additions of water immersion objectives and a deep-sectioning confocal spinning disk to the Cytation C10 add significant new capabilities for researchers requiring the best imaging performance for live-cell and 3D applications,” stated Caleb Foster, associate vice president of marketing in Agilent’s Cell Analysis Division. “As the demands continue to grow for more complex physiologically relevant live-cell models, the Cytation C10 will be an invaluable and transformative research tool to support these imaging application areas.”

Designed as an affordable, high-performance confocal microscopy system, the Cytation C10 employs high-quality components, including a Hamamatsu scientific CMOS (sCMOS) camera, Olympus objectives, and laser-based illumination. Onboard environmental controls, widefield fluorescence, brightfield, and phase contrast optics further enhance the system’s capabilities. Additionally, integrating it with the Agilent BioTek BioSpa 8 automated incubator enables efficient multi-plate live-cell analysis.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

.

Contacts

Naomi Goumillout
Agilent Technologies
+1.978.314.1862
naomi.goumillout@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Naomi Goumillout
Agilent Technologies
+1.978.314.1862
naomi.goumillout@agilent.com

More News From Agilent Technologies Inc.

Agilent Reports Second-Quarter Fiscal Year 2025 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.67 billion for the second quarter ended April 30, 2025, representing growth of 6.0% reported and up 5.3% core(1) compared with the second quarter of 2024. Second-quarter GAAP net income was $215 million, or $0.75 per share. This compares with $308 million, or $1.05 per share, in the second quarter of 2024. Non-GAAP(2) net income was $373 million, or $1.31 per share during the quarter, compared...

Agilent Names August Specht as Chief Technology Officer

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced August Specht, Ph.D., has been named the company’s Chief Technology Officer. Specht, previously vice president of Global R&D for the Chromatography and Mass Spectrometry Division at Thermo Fisher Scientific, will join Agilent on June 9. “We are thrilled to welcome August Specht to the Agilent team as we further accelerate the pace of innovation in an ever-changing world through our Ignite Transformatio...

Agilent Announces the Enhanced 8850 Gas Chromatograph: Compact, Powerful, and Now Mass Spec-Connected for Superior Analytical Performance

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the latest enhancements to the Agilent 8850 Gas Chromatograph (GC), including compatibility with single and triple quadrupole mass spectrometry (MS) systems and related tools and technologies to improve laboratory productivity. The unique design and compact size of the 8850 GC make it one of the fastest and smallest benchtop GC/MS available. It is explicitly designed for labs that require high speed and hi...
Back to Newsroom